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Abstract 
The Effect of Diabetes on Fracture Repair: Alterations in Angiogenesis and 
Apoptosis. 
An abundance of evidence has emerged demonstrating a close link between diabetes and 
significantly impaired fracture healing. Previous studies have determined that repair of 
fractures in diabetic animals is characterized by calluses with decreased size and bone 
formation. To further investigate the possible reasons for the decreased callus size we 
undertook a detailed histologic and immunohistochemical analysis focusing on the 
apoptosis of bone cells and angiogenesis that occurs during fracture healing. 
Angiogenesis was determined in the fractures by quantitative immunohistochemical 
analysis using the antibody to CD34. Cells expressing CD34 are found in the endothelial 
lining of blood vessels. Apoptotic cells were stained using the Apoptag Peroxidase In 
Situ Apoptosis Detection Kit. The decision to target these two parameters was based on 
the concept that enhanced cell death and decreased angiogenesis may limit the repair 
process. We used a well characterized type 1 diabetic animal model; the streptozotocin 
induced diabetic mouse (n=8), and a nondiabetic control group (n=7). Three weeks after 
establishing diabetes, tibia fractures were induced. The mice were euthanized 12, 16 and 
22 days after fracture. The 16 day samples were processed, embedded, sectioned and 
stained for analysis. The size of the fracture callus, and the amount of new bone and 
cartilage were determined using slides stained with H&E, masson trichrome and safranin-
O/fast green, respectively. The results showed that the diabetic groups have statistically 
two fold more apoptotic cells per callus (p<0.05). We also found that the number of 
vessels located in the areas of immature new bone were twice as high in the normal group 
VI 
as the diabetic (p<0.05). The results suggest that the reduced vascular supply and the 
increase apoptosis during the callus remodeling may lead to the reduced callus size and 
poor healing in diabetic osseous healing . 
Vll 
Introduction 
Diabetes mellitus is a disease marked by high levels of blood glucose resulting 
from defects in insulin production , insulin action , or both . There are several causes of 
diabetes, auto immune destruction of the body's insulin producing cells , insulin 
resistance, genetic disorder , drug use , illness and surgery, to list a few 1• As the causes 
are many, so are the resulting complications of the disease; poor wound healing , heart 
disease, periodontal disease , eye disease , high blood pressure and others 1• The 
complications and their symptoms are often the person's first indication of the disease 
and if left undiagnosed or untreated they could prove life threatening 1• 
According to the American Diabetes Association (ADA) , diabetes is the fifth-
deadliest disease in the United States 1• They estimate that 20.8 million people , 20 years 
or older, have diabetes with 6.2 million remaining undiagnosed. The non-hispanic white 
population has the highest prevalence of the disease with 13 .1 million , the non-hispanic 
black population being second with 3 .2 million 1• 
A disease affecting this many people has a large impact on the economy. The 
ADA found that the total annual economic cost of diabetes averages around 132 billion 
dollars compared to 44 billion in 1997 2• This would suggest that the epidemic is 
spreading, likely due to the nation ' s trend towards more inactive lifestyles 2• These costs 
do not take into account the diabetes-related hospitalizations, lost work days and 
permanent disability costs. In order to take control of this disease the population as a 
whole needs to learn more about diabetes , from what the risk factors are, to its effect on 
the body and the early warning signs. 
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Literature Review 
Diabetes Mellitus 
Though diabetes mellitus in general is a disease of elevated blood glucose the 
principal two forms vary in many aspects. Type I diabetes, or juvenile onset diabetes, is 
characterized by autoimmune destruction of the insulin-producing beta cells of the islets 
of Langerhans in the pancreas, leading to a deficiency of insulin 3. As the alternative 
name suggests, the onset of type I diabetes is usually during childhood or early 
adolescence. Commonly people affected are healthy and of a normal weight. Onset of 
symptoms are sudden, however overt diabetes may not develop for several years. 
Symptoms for type I diabetes are exaggerated weight loss, fatigue, irritability and the 
three cardinal signs of polyuria (frequent urination), polydipsia (unquenchable thirst) and 
polyphagia ( extreme hunger) 3. Untreated Type I diabetes can lead to the acute 
complication of diabetic coma caused by diabetic ketoacidosis, which can be fatal. 
Persons diagnosed with this type of diabetes have no internal means to control the body's 
blood glucose levels and therefore are dependent on daily insulin administration 
throughout life. In addition, strict monitoring of blood glucose levels must be performed 
frequently. Prevention is impossible due to the inability to control the risk factors: 
genetics, .environment and auto immune disorder 3. Type I diabetes only accounts for a 
small percentage of diabetes cases in the United States 3. 
Type II diabetes is an adult onset disease and makes up a majority of all 
diagnosed and undiagnosed diabetes cases 4• The risk factors associated with this type 
are family history, impaired glucose metabolism , physical inactivity, and obesity 5. 
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Persons who develop type II diabetes exhibit two changes in glucose metabolism. The 
first is a reduced response to insulin by peripheral cells, and the second an impaired 
secretion of insulin by the pancreatic beta cells. Many of the persons diagnosed with type 
II diabetes can control the disease with increased physical activity, decreased 
carbohydrate intake and weight loss; more resistant cases will supplement this with oral 
antidiabetic medications 5. Type II diabetes may go unnoticed for years because visible 
symptoms are typically mild, non-existent or sporadic. Commonly, this undiagnosed 
disease leads to future more severe complications 6. 
Pathogenesis of Diabetes 
Though genetic susceptibility plays a role in the pathogenesis of diabetic 
complications, studies have shown that chronic hyperglycemia constitutes as a major 
initiator. Under normal conditions, muscle and adipose cells are able to increase uptake 
of glucose when they are exposed to hyperglycemia, so that the body's internal glucose 
concentration stays constant 7 . In diabetes, the muscle and adipose cells have an impaired 
glucose metabolism and thus, are not able to uptake glucose efficiently 8. 
Hyperglycemia, therefore, leads to high glucose levels within the body of the diabetic 
resulting in complications in the internal mechanisms of a variety of other cells. The 
exact mechanisms by which this occurs has not been fully elucidated but several, well-
research~d theories have arisen. 
The study by Nishikawa et al. carefully characterized four major molecular 
signaling mechanisms activated by hyperglycemia 9. These include activation of protein 
kinase C pathways (via diacylglycerol), increased hexosamine pathway flux, increased 
advanced glycation end-product (AGE) formation, and increased polyol pathway flux 9. 
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These pathways reflect a single hyperglycemia-induced process, namely mitochondrial 
reactive oxidative stress production, which may be especially important in initiating 
events linked to inflammation and apoptosis 10-12• 
Advanced glycation end-products have been shown to induce apoptosis of 
fibroblastic and osteoblastic cells and to inhibit the up-regulation of angiogenic factors 
13
• 
14
• It is thought that the accumulation of AGE proteins leads to the tissue damage 
through three different mechanisms. The first is via the modification of intracellular 
proteins involved in the regulation of gene transcription 8. The second mechanism is that 
AGE precursors can diffuse out of the cell and modify extracellular matrix molecules 
which changes signaling between the matrix and the cell and causes cellular dysfunction 
8
. The third mechanism is the modification of circulating proteins in the blood, again via 
diffused AGE precursors 8• These modified proteins then bind to AGE receptors causing 
the production of inflammatory cytokines and growth factors, which in tum enhance 
inflammation, stimulate apoptosis, or negatively affect matrix producing cells 15-17_ 
With chronic hyperglycemia, AGE accumulation is greatly accelerated 18. 
The diabetes enhanced activation of protein kinase C pathways also increases 
apoptosis and inflammation by stimulating and prolonging cytokine production 19• Once 
such cytokine, TNF-a, is found to be elevated in diabetes and can directly promote 
insulin resistance 20 . Naguib et al. found that that cytokine dysregulation associated with 
prolonged TNF expression represents a mechanism through which bacteria may induce a 
more damaging inflammatory response in diabetic individuals 21• 
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Bone 
Within the human body two types of bone exist. Flat bones are found in areas 
needing extensive protection or broad surface area for muscular attachment. The second 
type, long bones, act as the support structures and afford the body its height. As their 
purposes are different so is the way in which both are developed. 
Long bone development begins with a compact grouping of mesenchymal cells 
which under stimulation differentiate into chondrocytes 22 . The resulting chondrocytes 
produce a matrix which serves as the bone's cartilaginous template. After a suitable 
matrix has been laid down by the cells, the near approach of blood is necessary before 
calcification occurs 23 . The chondrocytes discontinue the secretion of collagen and begin 
secreting alkaline phosphatase. Due to the cartilage matrix calcification oxygen, 
nutrients and cellular wastes can no longer diffuse through to supply the chondrocytes 23 . 
This leads to hypertrophy then programmed cell death, or apoptosis, and leaves behind a 
scaffolding of calcified cartilage. Periosteal buds invade the space left by the 
chondrocytes. The blood vessels provide the hemopoietic cells that will later form the 
bone marrow and the osteoblastic and osteoclastic cells with the capacity to begin 
replacing the cartilage by bone 24• This form of development is referred to as 
endochondral ossification. Secondary ossification centers form at the ends of the bone 
and und~rgo the same transformation as above. These two centers meet at the epiphyseal 
plates that continue growth into adolescence. 
Flat bone development occurs via intramembranous ossification 25 . Unlike 
endochondral ossification, cartilage is not involved in this process 26 . In flat bones the 
mesenchymal cells condense into vascularized layers of immature connective tissue. The 
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cells that differentiate into osteogenic cells form bony spicules, those that become 
osteoblasts increase the spicule size to form trabeculae. The majority of osteoblasts 
undergo apoptosis but some osteoblasts are eventually trapped within the trabeculae, at 
which time they convert into osteocytes which maintain the matrix 27 . As growth 
continues, trabeculae become interconnected and woven bone is formed. 
After formation, bone continues to undergoing remodeling 28 . The ability to 
remodel is vital to mineral homeostasis, mechanical stability and late stage fracture repair 
28
. Remodeling involves a coupled process between the interaction of osteoblast and 
osteoclast and involves five stages 29• The first is activation which is the recruitment of 
osteoclasts to a bone surface and signal coupling of osteoblasts. The second is resorption 
by the osteoclasts of mineral matrix and old bone. Third is reversal of the process with 
recruitment of new osteoblasts in the matrix. The fourth stage is formation of new tissue 
and the last stage is the resting state of the bone surface. The remodeling process 
becomes slightly lopsided with age where the deposition of the bone is less than the 
amount resorbed, leading to a cumulative loss of bone mass. 
Similar to long bone formation, the replacement of cartilage by bone is also 
utilized during fracture repair 30 . Immediately after injury occurs there is a release of 
blood cells into the damaged tissue. Repair begins with the constriction of the blood 
vessels to discontinue this bleeding. The blood cells then form a blood clot, known as a 
hematoma. As these cells die off the mesenchymal cells within the same area proliferate 
along with capillaries to form granulation tissue 31• It is from this tissue that the 
mesenchymal cells differentiate into chondrocytes that form hyaline cartilage 25 . 
Periosteum, the connective tissue membrane covering the bone, is the primary source of 
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precursor cells which develop into the osteogenic cells necessary for joining the fractured 
bone. The periosteal cells develop into both osteoblasts and chondroblasts which 
together form woven bone. Eventually the hyaline cartilage unites with the woven bone 
of the periosteum to form the fracture callus 25 . At this stage lamellar bone replaces both 
the woven bone and hyaline cartilage to form mineralized matrix. Forming blood vessels 
penetrate the cartilage matrix along with additional osteoblasts 32 . Eventually the original 
fracture callus is completely replaced with trabecular bone. The trabecular bone is slowly 
resorbed by osteoclasts and replaced with compact bone resembling the original bone , as 
occurs in bone remodeling 28 . 
Bone is a dynamic tissue , which throughout life is continually being formed and 
resorbed 28• 33 . This remodeling and reorganization of bone tissue is the result of many 
a well orchestrated series of events and cellular components. 
Cellular Components of Bone 
Chondrocytes 
Chondrocytes are the only cells found in cartilage 23 . They are responsible for 
forming and maintaining the cartilaginous matrix, which consists mainly of collagen and 
proteoglycans 23 . The cells undergo a defined and highly controlled maturation program 
from proliferating, to prehypertrophic and finally hypertrophic chondrocytes 23 . The 
hypertrophic chondrocytes eventually form a calcified matrix and then are removed via 
apoptosis leaving spaces within the central region of the cartilage template 26. These 
spaces are invaded by osteoclasts and then by the osteoblasts and newly formed blood 
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vessels which use the remaining mineralized matrix as a template for trabecular bone 
formation 23 . 
Osteoblasts 
Osteoblasts arise when mesenchymal cells of the bone marrow or periosteum 
differentiate under the influence of a plethora of growth factors and cytokines 29. They 
are large basophilic cells with a substantial rough endoplasmic and golgi apparatus. They 
are designed to synthesize organic matrix (predominately type I collagen , 90%) or 
osteoid material in amounts necessary for bone formation 34 . The average lifespan of 
these cells is from 1 to 10 weeks where after they disappear through apoptosis, transform 
into osteocytes or into bone lining cells (thought to play an important role in the 
activation of bone remodeling) 27. Osteoblasts mediate the arrangement of the extra 
cellular matrix fibrils , the resorption carried out by osteoclasts and synthesis of growth 
factors. Osteoblasts express a characteristic enzyme , alkaline phosphatase which has been 
used as an indicator of osteoblastic activity 35 . 
Recent studies have implicated osteoblasts as important regulators of 
angiogenesis 36-38 . They have found that vascular endothelial growth factor (VEGF) , a 
potent direct-acting angiogenic peptide , is highly expressed by osteoblastic cells in vitro. 
VEGF expression by these cells is thought to be regulated by a number of cytokines , 
growth factors and conditions including inflammation and hypoxia 38 . 
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Osteocytes 
Osteocytes, as previously mentioned, are formed when an osteoblast has become 
embedded in the bone matrix. The remaining osteoblasts and newly formed osteocytes 
maintain a communication via dendritic processes that contain transmembrane proteins 
and integrins, acting as links allowing the passage of intercellular messengers 28• 33 . 
Osteocytes are star shaped cells that occupy lacunae. They communicate amongst 
themselves through canaliculi. Osteocytes are the most abundant cell in the bone and 
functions to maintain the bone tissue and act as sensors of mechanical stress. 
Osteoclasts 
Osteoclasts are the cells responsible for the degradation and resorption of bone 29 . 
These large cells originate from the bone marrow hematopoietic stem cells, which also 
serve as the precursors of macrophages and monocytes 33 . Osteoclasts are multinucleated 
and rich in mitochondria and vacuoles. They contain tartrate-resistant acid phosphatase 
(TRAP), which allows the cells to dephosphorylate proteins 33 . It is also what is targeted 
by stains used to identify osteoclasts 39 . 
Macrophage-colony stimulating factor produced by the osteoblasts is an essential 
factor in osteoclastogenesis 40. Its presence stimulates the formation of the giant 
multinucleate cells though it does not affect the osteoclastic activity. The regulation of 
the osteoclast activity is stimulated by RANK and other cytokines 41• The interaction 
between RANKL (Receptor Activator of Nuclear Factor KB ligand) and its receptor 
RANK (Receptor Activator of Nuclear Factor KB) initiates osteoclastic activity and 
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differentiation. OPG ( osteoprotegerin) acts as an inhibitor by competitively binding with 
RANKL and blocking the osteoclastic differentiation. 
Over the last several years several cytokine mediators of osteoclast formation and 
activity have been identified, including interleukin-1 (IL-1 ), tumor necrosis factor- a 
(INF-a), and interleukin IL-6. These bone resorption-stimulating cytokines promote 
osteoclast development, by inducing RANKL on stromal cells 42 . In addition, TNF can 
induce osteoclast through a RANKL independent pathway. Not only are they able to 
stimulate osteoclast formation and bone resorption but they also play a role in the 
recruitment of osteoclast progenitor cells to the inflammatory site and also for the fusion 
of these cells to multi-nucleated osteoclasts 42 • Once activated, osteoclasts move to areas 
of microfracture in the bone by chemotaxis. The larges cells lie in a small cavity called 
Howship's lacuna, formed from the digestion of the underlying bone 43 . The sealing zone 
is the attachment of the osteoclast's plasma membrane to the underlying bone . The 
osteoclast releases hydrogen ions into the cavity, acidifying and dissolving the 
mineralized bone matrix. In addition, several hydrolytic enzymes are released to digest 
the organic components of the matrix . The osteoclast has a ruffled border which 
enhances its surface area. Products of digestion of the bone matrix include calcium and 
phosphate ions 43 . These ions are absorbed into small vesicles which move across the cell 
and eventually get released into the extracellular fluid, thus increasing levels of the ions 
in the blood . Osteoclast bone resorption requires only a fraction of the time required by 
osteoblasts to replace resorbed bone 43 . 
The effects of cytokines that stimulate osteoclast formation and bone resorption 
seem to be counteracted by other cytokines that inhibit the same processes 42 . IL-4, IL-
10 
10, and IFN-y and other cytokines have been found to block osteoclast development 42 . 
The inhibitory cytokines cause their effects either indirectly, by affecting osteoblasts, or, 
in some cases, directly, by affecting the osteoclast progenitor cells 42 . It is likely that it is 
the balance between the regulatory cytokines will determine the quantity of osteoclasts 
formed and their activity, and thus the degree of bone loss overall. 
Angiogenesis 
Angiogenesis describes the formation of capillaries from preexisting vessels. 
This occurs either via intussusception, which is the formation of a vessel from existing 
endothelium, or via vasculogenesis , which is spontaneous blood-vessel formation from 
circulating endothelial progenitor cells 44 • Both of the methods serve different but 
important roles in the development of new blood vessels . Vasculogenesis is invasive and 
thus able to bridge vascular gaps such is necessary in healing 44 . Its disadvantage is that 
it occurs slowly and relies heavily on cell proliferation. Intussuspection on the other 
hand, can cause an increase in the number of capillaries without a corresponding increase 
in the number of endothelial cells, therefore occuring in hours and even minutes 44 . 
Two growth factors have been deemed major contributors to endothelial cell 
proliferation, VEGF and FGF-2. VEGF, vascular endothelial growth factor, is a dimeric 
glycoprotein with structural homology to platelet-derived growth factor 37 . It is highly 
specific mitogen for endothelial cells in vitro, an it has angiogenic properties in vivo. In 
the presence of this growth factor endothelial cells will proliferate and migrate, 
eventually forming tube structures resembling capillaries 13• 45 ' 46 . VEGF also produces 
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vasodilation and an increase in vascular permeability hence, is one of the the first growth 
factor produced in hypoxia and is a key factor in fracture repair 47 . 
Fibroblastic growth factor-2 (FGF-2), is a wide-spectrum angiogenic factor shown 
to induce survival and proliferation as well as migration of endothelial cells both in vivo 
and in vitro 48' 49 . It drives the physical organization of endothelial cells into tube-like 
structures 37 and also plays a role in early fracture repair by stimulating the proliferation 
of fibroblasts that give rise to granulation tissue. Studies have found that FGF-2 may 
regulate VEGF expression in osteoblastic cells by increasing the levels of several 
cytokines that have been implicated in VEGF expression 37 . 
Bone formation relies heavily upon an adequate vascular supply. This is 
supported by the findings that vascularized bone grafts maintain more osseous mass than 
nonvascularized bone grafts, the interruption of blood supply to bone results in avascular 
necrosis, osteocyte survival requires close proximity to nutrient vessels, and there exists a 
close correlation between the rate of osteonic bone deposition and the vascular surface 
area 
50
' 
51
. Additionally, during endochondral bone development and repair is the invasion 
of hypertrophic chondrocytes with new capillaries from existing blood vessels in the 
developing periosteum 52. Osteogenic cells associate with the invading vasculature and 
establish the primary spongiosa as calcified cartilage is removed. This results in the 
formation of a scaffold with which osteogenic cells associate and begin to develop bone 
52 
Several diseases are the result of failure or insufficient blood vessel formation. 
The presence of blood vessels where there should be none may affect the mechanical 
properties of a tissue, increasing the likelihood of failure, such as seen in age-related 
12 
macular degeneration 53 . On the other hand , the absence of blood vessels in a repairing or 
otherwise metabolically active tissue may retard repair or some other function , as noted 
in bone formation 50 . Research in this area is attempting to find new ways to exogenously 
and endogenously control angiogenesis. 
Apoptosis 
Apoptosis is a form of cell death in which a cell actively pursues a course toward 
death upon receiving certain stimuli. It acts as a homeostatic and defense mechanism to 
maintain cell populations in tissues and also plays a role in development and repair 27 . 
Physiological cell death plays a role in the removal of virus-infected cells by cytotoxic T 
cells, the elimination of autoreactive immune cells and cells that have been damaged, the 
reconstitution of cartilage and bone, and more 32• When physiological cell death that 
normally should occur is inhibited, inappropriate physiological cell death may occur that 
is harmful to the body and forms the basis of disease. On the other hand, it is believed 
that the ability to survive is enhanced in transformed cancer cells because they are more 
resistant to apoptosis, they are no longer dependent on survival signals, and they can 
metastasize 54 . Excessive apoptosis therefore , causes hypotrophy whereas an insufficient 
amount results in excessive cell numbers. The apoptotic cell is characterized by cellular 
shrinkage, chromatin condensation, segmentation and finally, division into apoptotic 
bodies which are phagocytosed without initiation of inflammation 55 . 
Apoptosis may be triggered by a diverse range of cell signals, those that can occur 
intrinsically, such as events that target mitochondria ( e.g. reactive oxidative stress (ROS) 
and advanced glycation endproducts (AGE)) or extrinsic activation of cell surface 
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receptors via hormones, growth factors, nitric oxide or cytokines ( e.g. tumor necrosis 
factor superfamily) 56-58 . These triggers induce a chain of events that lead to activation of 
caspases and apoptosis. Caspases are proteolytic enzymes that are critical for the 
proteolytic events that occur in apoptosis. They degrade cytoplasmic and nuclear proteins 
involved in DNA repair and replication, RNA splicing, cytoskeletal structure, and cell 
division 59 . Once caspases are activated the morphological changes of apoptosis ensue. 
Cell proliferation and apoptosis are coupled events during fracture repair. Cell 
proliferation is active at the early stages, and apoptosis is active during the phase of callus 
remodeling 26 . This balance of proliferation, differentiation, and apoptosis of bone cells 
determines the size of chondrocyte and osteoblast populations at any given time 60• 61• 
Cells constantly receive signals from adjacent cells, hormones, and bone matrix that 
regulate their proliferation, activity, and survival. The lifespan of these cells are thought 
to be important in determining the amount of bone generated. There is considerable 
evidence that modulation of apoptosis of osteoblasts or their precursors plays a critical 
role in physiologic and pathologic bone remodeling and repair 62 . Landry et al. found 
that standard bone injuries in rats resulted in more osteoblasts and more apoptotic bodies, 
with an identical temporal relationship between the peak responses in the two parameters 
63
. Apoptosis has also been noted to precede recruitment of osteoclasts to areas where 
osteocytes have died after strain on the area has changed, as seen in bone remodeling 64 
Diabetes Effect on Angiogenesis 
Diabetes mellitus can cause many complications. Common acute complications 
such as, hypoglycemia and ketoacidosis may occur if the disease is not adequately 
controlled. The long-term and more serious complications result from hyperglycemia 
/ 
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and include microvascular complications and macrovascular complications 5• 7• 65 . The 
microvascular complications, or diabetic microangiopathy, involve a broad spectrum of 
dysfunctional changes in microvascular beds which lead to nephropathy, neuropathy, 
retinopathy and poor healing. 
According to the National Eye Institute, retinopathy is the most common diabetic 
eye disease and a leading cause of blindness in American adults. It is caused by blood 
vessel damage and causes vision loss in one of two ways: by the formation of abnormal 
and fragile blood vessels along the retina that leak blood leading to blurred vision and 
eventual blindness (proliferative retinopathy) or by the leaking of fluid into the center of 
the macula (macular edema) 66• 67. 
N ephropathy is the most common cause of chronic kidney failure and end stage 
renal disease in the United States 67' 68. It is more often seen in the poorly controlled 
chronic diabetic. In these diabetics the blood vessels of the glomeruli become thick and 
weakened which leads to a loss of protein from the blood into the urine and scarring of 
the glomerulus. 
N europathy is the most common complication of diabetes with an estimated 
prevalence of 20% 67' 69. It is partly the result also of a thickening and weakening of the 
blood vessels that are supplying the nerves. A study by Takeuchi et al. also contributes 
the pathology of the neurodegenerative processes to diabetes enhanced apoptosis of 
neurons and glia 70. N europathy can affect all peripheral nerves and therefore can 
essentially affect all major organ systems, symptoms range from tingling of the 
extremities to speech impairment. 
15 
Diabetic angiopathy has also been linked to bone defect related complications 
such as severe periodontal disease, osteopenia and delayed fracture healing 71-73• 
Diminished bone formation has been found to be most closely associated with patients 
that have microvascular complications in other organs and is supported by findings that 
serum levels of biochemical markers of osteogenesis are significantly lower in Type 1 
diabetic patients with microangiopathy 71 • 72 . 
In a healthy person primary vessel loss is compensated by the development of 
new vessels and the expansion of existing capillaries. The ability to do this comes from 
an osteogenic cell population and its interaction with the cytokines and stimulating 
factors, both originating from the blood supply of the damaged area 13• 50• 74 . In diabetes , 
the compensation is not sufficient and it is not clear whether the incompetence is due to 
the cell population or the level of cytokines and factors. The effects of an insufficient or 
interrupted diabetic angiogenic response in fracture repair appear to inhibit osseous 
regeneration 13. 
Diabetes Effect on Bone 
Diabetes mellitus has been widely associated with bone complications such as 
osteopenia, severe periodontal disease, increased risk of fracture and decreased bone 
remodeling 75-77 . The elevated glucose levels in both type I and II diabetics disrupt 
several pathways and cellular functions that contribute to the bone deficits. Type II 
diabetics tend to display low bone turnover which results in cumulative bone loss as a 
person ages 35• 78• 79 . The bone that is formed may have an increased density at the early 
stages of diabetes but lack tensile strength, rigidity and have reduced collagen content 71' 
16 
80
, 
81
. Impaired calcium uptake and the reduced ability of the bone to remodel lead to 
frequent stress fractures in type II diabetics 82 . 
Type I diabetics also carry an increased risk of fracture though for different 
reasons. The bone in type I diabetics undergoes increased bone resorption and decreased 
bone formation resulting in reduced mineral density and mass 80' 83 . The increased 
resorption may also contribute to the reduced cortical bone thickness. 
It is also widely established that diabetes causes delayed union and healing in 
bony fractures 82' 84 . These diabetic fractures are characterized by calluses with decreased 
size and bone formation, and with impaired biomechanical properties. Though the exact 
mechanisms responsible for these alterations have not been identified, there have been 
several published theories. One such study showed that diabetic animals produce 
sufficient amounts of immature mesenchymal tissue but fail to adequately express genes 
that regulate osteoblast differentiation and proliferation 85' 86 . Kayal et al suggested that 
impaired fracture healing in diabetes is characterized by increased rates of cartilage 
resorption resulting in reduced callus size, decreased bone formation and poor 
mechanical strength frequently reported in diabetic fracture healing 87• Another study 
suggested advanced glycation endproducts contribute to diminished bone healing 14• This 
is obviously an area that could benefit from further research. 
Animal Model 
Previous research on diabetic mice has contributed greatly to the understanding of 
fracture healing and bone formation. Diabetes in mice is induced by the administration 
of streptozotocin, a genotoxic methylating agent that is targeted to the pancreatic beta 
cells 88 . High single doses of streptozotocin cause extensive ~-cell necrosis, while 
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multiple low doses induce limited apoptosis, which elicits an autoimmune reaction that 
eliminates the remaining insulin producing cells. 
Diabetic mice experience features similar to the uncontrolled diabetic, including 
polyphagia, polydipsia, hyperglycemia and weight loss 88 . The animals exhibit many of 
the complications including enhance susceptibility to infection and cardiovascular 
disease, retinopathy, alterations in angiogenesis, delayed healing and diminished growth 
factors 89• 90 . The findings with respect to bone also tend to correlate well with those of 
uncontrolled type I human diabetics. There is decrease in bone mineral content and 
density, in differentiation and proliferation of cellular bone components and in cartilage 
and bone formation 81• 91-94 . Long bone fractures of streptozotocin-induced diabetic 
animals exhibit smaller calluses with decreased bone formation, decreased proliferation, 
and differentiation of osteoblastic cells, along with a reduction in the mechanical strength 
compared with matched controls 81 ' 94' 95 . These deficiencies were shown to be improved 
by the administration of insulin treatment demonstrating that they are directly related to 
the diabetic condition and not an artifact of the animal model. 
Aims of Study 
The following study strives to provide further insight into the mechanisms of 
diabetes-associated delays in fracture healing. An abundance of evidence has emerged 
demonstrating a close link between diabetes and significantly impaired fracture healing. 
Previous studies have determined that repair of fractures in diabetic animals is 
characterized by calluses with decreased size and bone formation. To further investigate 
the possible reasons for the decreased callus size and poor osseous healing in diabetics 
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we undertook a detailed histomorphometric and immunohistochemical analysis focusing 
on chondrocytes, apoptosis of chondrocytes and bone cells and angiogenesis that occurs 
during fracture healing. The decision to target these parameters was based on the concept 
that enhanced cell death and decreased angiogenesis may limit the repair process. 
The size of the fracture callus, and the amount of new bone and cartilage were 
determined using slides stained with H&E, masson trichrome and safranin-O/fast green, 
respectively. In order to visualize the cells of interest within our calluses we chose the 
following stains and assays. We targeted the cells of angiogenesis with an 
immunohistochemical stain targeting CD34+ cells. CD34 is a cluster of differentiation 
molecule present on the endothelial progenitor cells and endothelial cells of blood vessels 
96
• 
97
. To stain the cells that had recently underwent apoptosis we used TUNEL (Terminal 
uridine deoxynucleotidyl transferase dUTP nick end labeling assay). This assay relies on 
the presence of nicks in the DNA which can be identified by terminal deoxynucleotidyl 
transferase, an enzyme that will catalyze the addition of dUTPs that are secondarily 
labeled with a marker 55• 
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Materials and Methods 
The following procedures were performed by Dr. Rayyan Kayal. 
Animals- Eight week old, male CD-1 mice purchased from Charles River 
Laboratories (Wilmington, MA) were rendered diabetic, as previously described(*), with 
streptozotocin (40 micrograms per 1 g body weight; Sigma S-0130, St. Louis, MO) in 10 
mM citrate buffer by intraperitoneal injection daily for 5 days. Control mice were treated 
identically, except that 10 mM citrate buffer alone was injected. Blood glucose was 
monitored daily (Accu-Chek, Roche Diagnostics, Indianapolis, Indiana) beginning one 
week after the last injection. Mice were considered to be diabetic when blood glucose 
levels exceeded 250 mg/dL in two consecutive measurements. To ensure that the 
diabetic state was maintained throughout the experimental period, glycosylated 
hemoglobin levels also were measured at the time of sacrifice using Glyco-tek affinity 
column kit (Helena Laboratories - Beaumont, Texas). Blood glucose levels of diabetic 
animals ranged from 254-600 mg/dL, with a mean of 411 mg/dL. Normoglycemic mice 
had blood glucose levels that ranged from 102-206 mg/dL, with a mean of 142 mg/dL. 
Glycosylated hemoglobin in diabetic animals ranged from 9.3-15.3, with a mean of 13.2, 
while the values in normoglycemic mice ranged from 5.1-6.7, with a mean of 6. 
Fractures of the tibia were induced 3 weeks after establishing diabetes, as 
previously described 25 . Animals were first anesthetized with ketamine (80 mg/kg) and 
xylazine (10 mg/kg) and a 27 gauge spinal needle was then inserted in the marrow space 
of the tibia for fixation. Next, the distal aspect of the leg was held in place on a stage and 
a blunt guillotine driven by a weight was dropped. This produced uniform and 
reproducible closed, simple mid-diaphyseal transverse fractures of the tibia. Animals 
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were euthanized 16 days after fracture by an overdose of ketamine/xylazine solution. At 
the time of euthanasia, tibias were harvested and the associated muscle and soft 
connective tissue were grossly removed, using care to leave the fracture calluses intact. 
Radiographic assessment of the fractures was performed immediately after fracture and at 
the time of euthanasia. All procedures were approved by the Boston University Medical 
Center Institutional Animal Care and Use Committee. 
Histology and Immunohistochemistry 
The harvesting, decalcification, processing and embedding of the specimens were 
performed by Dr. Rayyan Kayal. 
The harvested tibia with a small amount of surrounding muscle and soft tissues 
were fixed for 72 hours in cold 4% paraformaldehyde and decalcified for 2 weeks by 
incubation in cold Immunocal (Decal Corporation, Congers, NY). After decalcification, 
the internal fixation pin was removed and the fracture center was determined by visual 
and radiographic assessments. The resulting callus was processed and embedded in 
paraffin, with the distal portion of the fracture facing the cutting surface. Serial 5 µm 
thick cross-sections were cut at intervals of 1 00µm, beginning with the distal portion of 
the callus through the center and to at least 1 mm proximal of the center. Specimens were 
then mounted on slides and prepared for histostaining, immunohistochemistry and 
histomorphometric analysis. 
The size of the fracture callus, and the amount of new bone and cartilage were 
determined using slides stained with hematoxylin and eosin (H &E), masson trichrome 
and safranin-O/fast green, respectively. H & E is a standard stain that allowed easy 
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visualization of the callus perimeter. Masson trichrome stain was used to measure the 
amount of new bone formation. Similarly , safranin-O/fast green distinguishes cartilage 
from bone and non-cartilage connective tissues and was used to quantify the amount of 
mature cartilage formed in the calluses 98' 99 . Measurements of area were determined 
using Image ProPlus software (Media Cybernetics , Silver Spring , MD), as previously 
described 99 . When necessary , reference to differently stained , adjacent serial sections 
was used to discriminate between bone , cartilage and non-cartilage connective tissues 
during quantitative measurements. 
As an added visual aid, we took masson trichrome and safranin-O/fast green 
stained slides at 1 00µm increments beginning with the distal portion of the callus through 
to the proximal end of the callus. The images were captured as jpegs on Image Pro Plus 
software and then manipulated in Adobe Photoshop 6.0. The resulting Photoshop files 
were then retrieved using Amira , a 3D visualization and modeling system (Amira , 
Konrad-Zuse-Zentrum). Upon completion the programs were able to give us a 3-D 
reconstruction of the newly formed bone and a separate 3-D reconstruction of the 
cartilage. This was done for one representative animal from each group. 
Angiogenesis was determined in diabetic and nondiabetic fractures by 
quantitative immunohistochemical analysis using the antibody to CD34. Serial sections 
of the above mentioned specimens at the center and 1.0mm proximal and distal to the 
center. The paraffin embedded specimens were mounted on ProbeOn Plus slides (Fisher 
Scientific) . Immunostaining was performed using the 
immunoperoxidase/diamindobenzidine technique (streptavidin-biotin-horseradish 
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peroxidase complex- Histostain Plus kit; Zymed Laboratories Inc. 85-9943) according to 
the following protocol: 
1) Deparaffinize slides and hydrate to 80%, rinse well with dH20 
2) Fill wells of microprobe equipment with endogenous oxidation blocking solution 
and absorb, incubate in the dark for 10 minutes at room temperature (RT) 
3) Using the endogenous avidin/biotin blocking kit 
a. apply one drop into each well of reagent A and absorb, incubate for 10 minutes 
at RT, rinse with PBS 
b. apply one drop into each well of reagent Band absorb, incubate for 10 minutes 
at RT, rinse with PBSx2 
4) Fill wells with blocking solution (TNB from TSA kit), drain slides on paper 
towel, then place slides into wells to absorb blocking solution, incubate at 3 7° for 
15 minutes -- drain, DO NOT RINSE! 
5) Place primary antibody at concentration of 1 :50 and controls in wells, incubate at 
3 7° for ~40 minutes ( dilute with TNB) 
*controls must be done using normal serum diluted to same concentration as the 
primary antibody- acts as the negative control 
6) Rinse slides with PBS for 5 minutes at RT 
7) Place secondary antibody in wells and absorb ( diluted to manuf. 
recommendations using TNB), incubate at 37° for 20 minutes 
8) Rinse slides with PBS for 5 minutes at RT 
9) If using a biotinylated secondary antibody at concentration of 1:500, fill wells 
with LABS A reagent and absorb, incubate at 3 7° for 15 minutes 
10) For TSA only- dilute biotinyl tyramide stock soln 1 :50 using IX amplification 
diluent, fills wells and absorb, incubate for 5-10 minutes at RT 
11) For TSA only- dilute SA-HRP with TNB buffer 1 :50 or 1: 100, fill wells and 
absorb, incubate at 3 7° for 20 minutes 
12) Rinse slides with PBS for 5 minutes at RT 
13) Fill wells with prepared chromogen substrate (DAB) and absorb, incubate for 1 
minutes at RT (monitor color under microscope) 
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14) Rinse with dH20, place prepared enhancer to wells and absorb, incubate for 1 
minutes at RT (monitor color under microscope) 
15) Counterstain with hematoxylin 
16) Dehydrate slides and coverslip 
Rat anti-CD34 antiserum (1 :50) (MEC Primary antibody 
14.7, Abeam ab8158) 
Biotinylated anti-rat IgG (1 :500) (Sigma Secondary antibody 
B-1399) 
Normal rat serum IgGA2 (Invitrogen) Control 
Chromagen DAB kit (Invitrogen 00- Chromagen substrate 
2020) 
A vidin/Biotin blocking buffer Blocking buffer 
(Invitrogen 00-4303) 
TSA Biotin System (PerkinElmer NEL Signal amplification kit 
700A) 
Apoptotic cells were stained for using the Apoptag Peroxidase In Situ Apoptosis 
Detection Kit (Chemicon International S7100) TUNEL assay, according to 
manufacturer ' s protocols. Serial sections at the center, and 1.0mm proximal and distal 
were stained using the kit and diaminobenzidine chromogen (lnvitrogen 00-2020). 
Osteo/chondroclast formation was determined by counting the number of cells 
that had positive staining with tartrate-resistant acid phosphatase (TRAP) stain. The 
protocol for this stain was completed , as previously described 100. 
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Histomorphometric Analysis 
Fifteen animals were used for histomorphometric evaluation, and these were 
distributed so that there were 8 animals for the diabetic 16 day time point and 7 animals 
for the 16 day control group. For each animal, measurements were made at 5 points 
across the callus: 1) center, 2) 0.5mm distal from center, 3) 1.0mm distal from center, 4) 
0.5mm proximal from center, and 5) 1.0mm proximal from center. For each point, 
measurements of callus size, new bone formation and cartilage area were made. For each 
measurement, 1-2 sections were analyzed to obtain a value for each animal. 
The analysis ofTUNEL stained specimens were done at 40x magnification, at the 
center of the fracture. In order for the cells to be counted as apoptotic they had to fit at 
least two of the following three criteria: darkly stained, round in shape and /or of uniform 
size. The counts were completed throughout the callus excluding the medullary canal. 
Counts were separated into apoptotic cells in cartilaginous areas and apoptotic cells in 
non-cartilaginous areas. The data was normalized by comparison with the corresponding 
tissue counts. 
The analysis of CD34 stained vessels were done at 40x magnification, at the 
center of the fracture, and 1.0mm proximal and distal. In order for the vessels to be 
counted as CD34 positive they had to fit the following criteria: dark, uniform staining, 
small round or linear appearance and uninuclear. The counts were completed by field 
(0.0576 mm2) throughout the callus in three distinct tissues; mature bone (interspersed 
with hematopoietic tissue, no cartilage present), immature bone (interspersed with little 
hematopoietic tissue, small amounts of cartilage present) and cartilaginous bone (within 
0.0072 mm2 of a large area of cartilage). 
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All counts and measurements were completed by one examiner under blind 
conditions. Data was used to calculate mean values per group per time point. This 
rigorous analysis scheme provided detailed data across most of the fracture callus, 
allowing us to formulate a comprehensive understanding of the healing dynamics. 
Statistical Analysis 
Data was presented as means and the statistical analysis between diabetic and 
non-diabetic groups for a given parameter was established by Student's t test, with P 
values of <0.05 considered statistically significant. 
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Results 
Figures 1-3. Callus area and new bone formation ( collaborative study): In a previous 
study from our laboratory it was confirmed that repair of fractures in diabetic animals is 
characterized by calluses with decreased size and bone formation 87• Mean values for 
both diabetic and control groups were compared for each of three time points post-
fracture: Days 12, 16 and 22. As shown in Figures 1-3 the size of the diabetic calluses 
are consistently smaller throughout the healing period. 
The formation of new bone was also analyzed during this study at the same three 
time points. The fracture calluses of the diabetic group (Figures 1B- 3B) contained less 
bone than those of the control (Figures lA- 3A). It was also found that at Day 16 both 
diabetic and control groups exhibited the largest increase in bone area and thus is an 
important time point for bone formation. 
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Figure 1 - Day 12 
A- Control 
Figure 2- Day 16 
A- Control 
Figure 3- Day 22 
A- Control 
B- Diabetic 
B- Diabetic 
B- Diabetic 
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Figures 4-5. Osteoclasts and cartilage area ( collaborative study): Premature loss of 
cartilage through increased clastogenesis was implicated as a possible reason for the 
diminished callus size. The study found that the diabetic group had almost double the 
number of clast cells at Day 16 (Figure 4A and 4B) with significantly less cartilage 
(Figure 5A and 5B) than the control animals. At the Day 12 time point the groups had 
identical amounts of cartilage thus suggesting that the capacity to form the cartilage was 
not impaired. 
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Figure 4- Osteoclasts 
A- Control 
Figure 5- Cartilage 
A- Control 
B- Diabetic 
B- Diabetic 
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Figure 6. Callus area: Based upon the findings of the previous study, the post-fracture 
time point we chose as the focus of our study is Day 16. The size of the fracture calluses 
in each diabetic and control animal was determine from the sum of area measurements 
taken at five points over a 2mm span centered at the fracture line. Mean values for both 
groups were compared. As shown in Figure 6A the size of the calluses in the diabetic 
group was consistently smaller throughout the callus. The total mean value for the 
diabetic group was 1.5-fold less than the normoglycemic group (Figure 6B). * diabetic 
was significantly different from normoglycemic (P<0.05). 
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Figure 7. New bone formation: The bone formation was analyzed in the same manner 
for each group. The diabetic calluses contained less bone than those of the normal group , 
as shown in Figure 7 A. The total mean value for the diabetic group was 1 .4-fold less 
than the normoglycemic group (Figure 7B). Figure 7C represents percentage of total area 
of new bone present throughout the callus. * diabetic was significantly different from 
normoglycemic (P<0.05). 
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Figure 7C- Percentage of total area of new bone present throughout the callus 
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Figure 8. Cartilage area: As expected we found a significant difference in cartilage 
between the diabetic and control groups at day 16. Figure 8A demonstrates the amount 
of cartilage across the 2mm proximal-distal dimension of the callus. The diabetic 
animals had significantly less cartilage at the central region and three out of the other four 
points (p<0.05). The total mean value for the diabetic group was 3-fold less than the 
normoglycemic group (Figure 8B). Figure 8C represents percentage of total area of 
cartilage present throughout the callus. * diabetic was significantly different from 
normoglycemic (P<0.05). 
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Figure 8C- Percentage of total area of cartilage present throughout the callus 
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Figures 9-12. Amira images of callus bone and cartilage: Amira software three 
dimensional reconstruction of the newly formed bone and a separate three dimensional 
reconstruction of the cartilage , both from a frontal sagittal view. This was done for one 
representative animal from each group. We noted that the size and amount of both new 
bone and cartilage were larger in the control animal. 
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Figure 13. Blood vessel formation: Our study also investigated whether or not diabetes 
induced alterations in angiogenesis. The expression of the vascular marker CD34 was 
quantified using immunohistochemistry. The numbers were counted at the center of each 
callus and at the distal and proximal ends . Mean values for both groups were compared. 
As shown in Figure 13, the control group had double the number of vessels located in the 
areas of immature new bone (p<0.05), and significantly more in the areas of cartilage 
bone interface. * diabetic was significantly different from normoglycemic (P<0.05). 
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Figure 13- Number of vessels present in the areas of cartilage/bone interface (CB) , 
immature new bone (IB) and mature bone (MB). 
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Figure 14. Apoptosis: Tunel positive apoptotic cells within bone and cartilage were 
counted in sections cut through the center of the callus. The diabetic group had 7-fold 
more apoptotic cells in the area of cartilage than the control group (p<0.05) (Figure 14A). 
In the non-cartilaginous area ( callus area excluding medullary cavity and cartilage area) 
the difference was 2.3-fold more in the diabetic also making the numbers statistically 
significant (p<0.05) (Figure 14B). * diabetic was significantly different from 
normoglycemic (P<0 .05). 
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Figure 15. Total tissue area per callus: The measurements of area for individual 
tissues within the callus were normalized to the total area of the callus and expressed as a 
percentage of total area. Figure 15A represents the percentage of hematopoietic space 
which is defined as the marrow spaces plus the resorption voids ( empty space) within the 
callus. Cartilage, new bone and void were then graphed together in a stacked column to 
easily compare the data to callus area (Figure 15B). 
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DISCUSSION 
The natural process of healing a fracture occurs with the formation of a stabilizing 
callus in which cartilage is initially formed, then resorbed and eventually replaced by 
bone 23 • Diminished bone formation and delayed fracture healing has been observed in 
patients with diabetes ' 0 ' · 102. To gain insight into how diabetes affects fracture healing, 
studies were carried out focusing on the impact of diabetes on the apoptosis of bone cells 
and angiogenesis. 
Studies have determined that repair of fractures in diabetic animals is 
characterized by calluses with decreased size and bone formation 81• 91• 93• This was 
reiterated by a collaborative study in our laboratory that compared three time points post-
fracture: Days 12, 16 and 22 87• We found that at Day 12 there was no significant 
difference between the callus size in diabetic and control groups but there was at the 16 
day time point. This suggests that the diabetes defect involves tissue loss rather than 
formation. The present study therefore, focused on the 16 day time point since both 
diabetic and control groups exhibited the largest increase in bone area at this point in the 
previous study. We also confirmed that the diabetic calluses were decreased in size, with 
findings of a 1.5 fold smaller callus produced by the diabetic mice. 
Diabetes and Apoptosis 
Cell proliferation and apoptosis are coupled events during bone development and 
repair. The balance of proliferation, differentiation, and apoptosis determines the size of 
chondrocyte or osteoblast populations at any given time, and the lifespan of these cells 
are thought to be important in determining the amount of bone generated 22 • Adequate 
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healing requires a sufficient number of cells to repair wounds. Therefore, modulation of 
apoptosis of osteoblasts or their precursors plays a critical role in physiologic and 
pathologic bone remodeling and repair. Enhanced apoptosis would hinder the repair of 
resorbed bone by reducing the numbers of available osteoblasts. 
Previous studies have shown that diabetic animals exhibit increased apoptosis 
both in wound and fracture healing 18• 103 which was consistent with our results. The 
diabetic group had 7-fold more apoptotic cells in the areas of cartilage than the control 
group and in the non-cartilaginous area the difference was 2.3-fold more in the diabetic. 
There is also considerable evidence that modulation of apoptosis and the lifespan of these 
cells and their precursors plays a critical role in determining the amount of cartilage and 
bone generated 59 . In this study, we can see this point reflected in the direct correlation 
between the amount of apoptosis and the amount of tissue formed in callus. As the 
apoptotic numbers increased the bone and cartilage formation decreased in accordance. 
In calluses with increased apoptosis the new bone formation was 1.4-fold less compared 
to the control group and the cartilage formation was 3-fold less. 
The bone fracture healing process requires a complicated interaction among 
inflammatory cells, biochemical mediators, extracellular matrix molecules, and 
microenvironmental cell population 81 • 94 . Any disruption in the normal cascade of events 
can cause a myriad of untoward effects. The hyperglycemia experienced by diabetic has 
been targeted as one such disruption leading to limited repair of injured tissue. It has 
been demonstrated that the hyperglycemic condition leads to activation of several 
pathways responsible for reactive oxidative stress production 104• In tum, this oxidative 
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stress plays a central role in the persistence of the inflammatory response and increased 
apoptosis of matrix producing cells noted in the diabetic human and animal model 18• 
A study review completed by Graves et al found that in diabetic individuals there is a 
exaggerated inflammatory response that leads to enhanced apoptosis of fibroblastic and 
osteoblastic cells 18• They attributed this to the dysregulation of tumor necrosis factor 
(TNF) and the formation of advanced glycation endproducts, both of which occur at 
higher levels in diabetic humans and animal models I os, 106• The enhanced loss of 
fibroblasts and osteoblasts through apoptosis in diabetics could contribute to limited 
repair of injured tissue, particularly when combined with other known deficits in diabetic 
wound-healing. 
Diabetes and Angiogenesis 
Several studies have reported that an insufficient or interrupted angiogenic 
response inhibits osseous regeneration 23• 37 . This was also reflected in our study. Our 
control group had 2 fold the number of vessels located in the areas of immature new bone 
than the diabetic group. The control groups showed corresponding calluses with 1.4 fold 
more new bone in comparison to the diabetic group. 
In diabetes, diminished bone formation has been found to be most closely 
associated with patients that have microvascular complications in other organs, supported 
by findings that serum levels of biochemical markers of osteogenesis are significantly 
lower in Type 1 diabetic patients with microangiopathy 71' 72. The angiogenic response is 
therefore not sufficient and though it is not clear why, there are several mechanisms that 
could be responsible. 
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In health, primary vessel loss after bone fracture is compensated by angiogenesis, 
or the development of new vessels and the expansion of existing capillaries 46 • The 
ability to do this comes from an osteogenic cell population and its interaction with the 
cytokines and stimulating factors, both originating from the blood supply of the damaged 
area 13• so, 74 . The ability of FGF-2 to increase VEGF expression by osteoblastic cells 
suggests that these factors may play an important role in the angiogenic response 
evidenced by healing bone 37 . Considering this, the collaborative study also assessed 
mRNA levels of vascular endothelial growth factor (VEGF) 87 . Levels of VEGF were 
found to be elevated in calluses both at 12 and 22 day 87 but were not sufficient enough to 
account for the difference in callus size and new bone formation between the diabetic and 
control groups. An article by Gerstenfeld et al. suggests that angiogenesis in fracture 
healing may be regulated by two separate pathways: a VEGF-dependent pathway and an 
angiopoietin-dependent pathway 107. They attribute the formation of larger vessel 
structures and the development of co-lateral branches from existent vessels to 
angiopoietin 1 and 2 and their receptors 107. The role of the angiopoietin pathway and its 
contributions in bone repair are not as well understood. Though recent studies show that 
some angiopoietin receptors are induced 3 to 5 fold during the initial periods of fracture 
healing 108• This may explain why in my thesis there was a significant 2 fold decrease in 
blood vessels in the diabetic group while Kayal and colleagues 87 found there was 
relatively little difference in VEGF, i.e. the angiopoeiten-dependent formation of vessels 
may be important in the decreased formation of vessels in the diabetic fracture healing. 
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Diabetes and Oral Health 
For sometime now diabetes has been linked to the destructive effects of 
periodontal disease. It has been found that diabetes leads to greater net periodontal bone 
loss and contributes to increased risk of tooth loss 73• 109• 110• The radiographs of alveolar 
bone height in long-duration diabetics exhibited significantly more extensive alveolar 
bone loss than in non-diabetics 111- 113• When diabetes types 1 and 2 are directly 
compared , both increase periodontal disease prevalence to a similar extent. 
The relationship between oral health and diabetes has been extensively studied, 
especially in its relation to periodontal health. New research is now being presented 
linking this disease to other oral health conditions, such as endodontic lesions 114-116• A 
study by Kohsaka et al found that in uncontrolled streptozotocin-induced diabetic rats, 
inflammation in the apical periodontal ligament and root resorption were more severe 117• 
This study also revealed histometrically that, in experimental rats, lesions in the 
periapical area were significantly larger than those in control rats 118• It has been found 
that diabetes mellitus is significantly associated with an increased prevalence of 
periapical periodontitis and that patients with diabetes have a reduced likelihood of 
success of endodontic treatment in cases with preoperative periradicular lesions 116• 117• 
119
• Therefore, it is not uncommon for those with diabetes who had endodontic treatments 
to have residual lesions after treatment, important when considering retreatment 116• 
This data on the diabetic effects of endodontic lesions and periodontal disease is 
not surprising since the pathology of both arises from the inability to repair hard and soft 
tissues, much like the previous study on fracture repair. The oral tissues are also 
dependant upon the presence of cells, such as osteoblasts, and an angiogenic response in 
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order to the form new bone following resorption. It is therefore reasonable to assume that 
the impairments that the diabetic experience during fracture repair may carryover to the 
response elicited by bacterial periodontal and endodontic challenges. 
Much like the studies on wound healing, it has been shown that accumulation of 
advanced glycation endproducts in the periodontium is correlated with an increase in the 
level of inflammatory mediators, which are associated with tissue destruction, 
predominately TNF-a and IL-6 120• 121• The formation of AGEs and inflammatory 
mediators could potentially contribute to the severity of tissue destruction in diabetics 
with endodontic lesions and periodontal disease by direct effects on osteoblastic cells, 
such as reduced expression of growth factors (e.g. VEGF), or indirectly through 
promoting inflammation and apoptosis of these matrix-producing cells . Along with the 
diminished capacity to form new bone, diabetes may make it more difficult to repair the 
loss of tissue that occurs in both endodontic lesions and periodontal diseases experienced 
by diabetic patients. It is important to note that when diabetes mellitus is under 
therapeutic control, periapical and periodontal lesions heal as readily as in nondiabetics 
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ENDODONTIC RAMIFICATIONS OF STUDY 
Increased 
Osteoclasts 
\ 
I DIABETES I 
/ l " 
Increased Bone Cell 
Apoptosis 
\ 
Decreased 
Angiogenesis 
I 
Increased Bone 
Loss 
Decreased Bone 
Re air 
Greater 
Periapical 
Patholo 
Impaired 
Endodontic 
Healin 
As seen in the above flow chart there are two main endodontics ramifications of 
this study. Within the diabetic , osteoclastogenesis may contribute to the increased 
formation of periapical lesions , noted in the first collaborative study , while the increase in 
apoptosis and decrease in angiogenesis may give insight into the impairment of healing 
as seen in endodontic lesions. 
A better understanding of the abnormalities in angiogenesis and apoptosis in 
diabetic wounds could lead to new targets for intervention. Discovery of the defects in 
these cells and the means to correct them could lead to development of therapies, 
biomarkers and imaging tools to improve the diagnosis and treatment of diabetic 
complications such as though seen in healing of endodontic lesions. 
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CONCLUSIONS 
We concluded that the diabetic group of mice had significantly more apoptotic 
cells present in both the cartilaginous and non-cartilaginous areas of the callus, and had 
significantly less blood vessels in the area of immature new bone and cartilage/bone 
interface. The resulting calluses of the diabetic group although initially similar, because 
consistently smaller than the normal group over time and contained less bone and 
cartilage by day 16. Therefore, it is conceivable that the biochemical basis for reduced 
bone formation in diabetes is the excessive removal of cartilage by diabetes caused by 
enhanced osteoclastogenesis coupled with greater apoptosis and an insufficient 
angiogenic response during callus formation. Investigating possible mechanisms to 
control diabetes enhanced osteoclastogenesis, pro-apoptotic cytokines and angiogenic 
growth factors may lay the groundwork for future manipulations of the developing bone 
microenvironment and ultimately improve the treatment of bone repair in the diabetic. 
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